Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $6.63 Average PT from Analysts

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) have received a consensus recommendation of “Buy” from the eight brokerages that are covering the stock, Marketbeat.com reports. Eight equities research analysts have rated the stock with a buy recommendation. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $6.63.

TSHA has been the topic of a number of research reports. JMP Securities reissued a “market outperform” rating and set a $5.00 price target on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Needham & Company LLC reiterated a “buy” rating and issued a $6.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Cantor Fitzgerald restated an “overweight” rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Chardan Capital reaffirmed a “buy” rating and set a $7.00 price target on shares of Taysha Gene Therapies in a report on Thursday, November 14th. Finally, Canaccord Genuity Group boosted their price objective on shares of Taysha Gene Therapies from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Friday, November 15th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp purchased a new stake in shares of Taysha Gene Therapies during the 2nd quarter worth approximately $1,018,000. Principal Financial Group Inc. purchased a new stake in Taysha Gene Therapies during the second quarter worth $48,000. Privium Fund Management B.V. acquired a new stake in Taysha Gene Therapies in the second quarter valued at $213,000. Rhumbline Advisers purchased a new position in shares of Taysha Gene Therapies in the second quarter valued at $413,000. Finally, The Manufacturers Life Insurance Company raised its stake in shares of Taysha Gene Therapies by 109.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 133,213 shares of the company’s stock worth $298,000 after buying an additional 69,487 shares during the last quarter. 77.70% of the stock is currently owned by institutional investors and hedge funds.

Taysha Gene Therapies Price Performance

Shares of NASDAQ:TSHA opened at $1.73 on Thursday. Taysha Gene Therapies has a 1-year low of $1.19 and a 1-year high of $4.32. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51. The stock has a market cap of $354.55 million, a P/E ratio of 2.75 and a beta of 0.79. The firm has a fifty day moving average price of $2.11 and a 200 day moving average price of $2.19.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.